MRD Testing in Myeloma: Can You Safely Step Down Treatment?
A plain-English guide to 10⁻⁵ and 10⁻⁶ sensitivity, NGF vs. NGS testing, and NCCN 2027 rules on maintenance de-escalation
Medical Disclaimer: This guide is synthesized from international clinical consensus guidelines and peer-reviewed literature. It is for educational purposes only and does not substitute for professional medical advice. Always consult your oncology team regarding diagnostic and treatment decisions.
💡 The Short Answer
Minimal Residual Disease (MRD) testing acts like a molecular magnifying glass that checks the first 1 to 3 mL of your bone marrow aspirate using Next-Generation Flow (NGF) or Next-Generation Sequencing (NGS, such as clonoSEQ) to see if even 1 myeloma cell remains among 100,000 (10⁻⁵) or 1,000,000 (10⁻⁶) normal cells after you reach a Complete Response (CR). Under the latest NCCN (v2.2027) and IMWG guidelines, reaching Sustained MRD Negativity—two negative tests at least 12 months apart paired with a negative whole-body FDG-PET/CT—is the single strongest predictor of long-term remission and can even overcome baseline high-risk genetics. Furthermore, NCCN v2.2027 supports using Sustained MRD Negativity in shared decision-making to safely step down 2-drug maintenance (such as stopping daratumumab after 24 months while continuing lenalidomide in the PERSEUS protocol), though patients with high-risk disease should remain on continuous maintenance rather than stopping therapy altogether.
Why This Matters
Imagine your multiple myeloma at diagnosis as a giant iceberg. The top of the iceberg above the water represents the symptoms and high M-protein numbers that show up on routine blood tests. When modern 4-drug induction therapy or an autologous stem cell transplant melts away the entire visible top of the iceberg—driving your blood and urine M-protein down to zero—you have reached a traditional Complete Response (CR).
Yet beneath the calm water, thousands of microscopic myeloma cells can still hide in the bone marrow. That hidden underwater base is Minimal Residual Disease (MRD). Understanding how MRD works gives you three reassuring advantages:
- MRD negativity is the strongest predictor of multi-year remission: Whether you started with standard-risk or high-risk genetics, driving your bone marrow down to MRD-negative (10⁻⁵ or 10⁻⁶) puts you in the best prognostic group for long-term progression-free survival.
- Being MRD-positive in remission is not an emergency: If your blood tests are zero (CR or VGPR) but your MRD test still detects a few cells, do not panic—many patients remain in a peaceful "dormant plateau" for years on maintenance therapy without relapsing.
- Sustained MRD negativity is helping patients step down heavy maintenance: Instead of staying on multiple drugs forever, proving that your MRD stays negative for 12 to 24 months now allows many patients on 2-drug maintenance to step down to a single oral medication with their doctor's guidance.
If you are preparing for your bone marrow procedure, start with our guide on bone marrow aspirate & biopsy. This guide explains how 10⁻⁵ and 10⁻⁶ testing works, when to check MRD, and what the NCCN 2027 guidelines say about reducing or stopping maintenance therapy.
📖 Key Terms in Plain English
| Term | Plain-English Meaning |
|---|---|
| MRD (Minimal Residual Disease) | Tiny numbers of myeloma cells hiding in the bone marrow after routine blood and urine tests have already reached zero (Complete Response) |
| 10⁻⁵ vs. 10⁻⁶ Sensitivity | How deeply the lab searched: 10⁻⁵ means finding zero myeloma cells out of 100,000 normal marrow cells (the international baseline standard), while 10⁻⁶ means zero out of 1,000,000 cells |
| NGF (Next-Generation Flow) | An ultra-fast MRD method (EuroFlow) that uses 8 to 10 colored laser tags to spot abnormal surface proteins on fresh bone marrow cells without needing a saved baseline sample |
| NGS (Next-Generation Sequencing) | A DNA-based MRD method (such as FDA-cleared clonoSEQ) that searches for your tumor's unique DNA barcode down to 10⁻⁶, requiring a saved bone marrow sample from diagnosis |
| Sustained MRD Negativity | Having two consecutive MRD-negative results (at 10⁻⁵ or deeper) taken at least 1 year (12 months) apart, with no positive test in between |
| Imaging Plus MRD Negativity | Combining a negative bone marrow MRD test in the hip with a completely dark whole-body FDG-PET/CT scan, proving no myeloma is hiding elsewhere in the body |
1. How the "Super-Magnifying Glass" Works: 10⁻⁵ vs. 10⁻⁶ and NGF vs. NGS
A standard bone marrow biopsy under a regular microscope only looks at a few hundred cells—it cannot tell the difference between 10,000 leftover myeloma cells and zero. To reach true MRD sensitivity, labs examine 2 million to 5 million bone marrow cells at once using one of two approved technologies:
| Feature | Next-Generation Flow (NGF / EuroFlow) | Next-Generation Sequencing (NGS / clonoSEQ) |
|---|---|---|
| How It Finds Myeloma Cells | Uses laser "facial recognition" to spot abnormal protein markers (CD138, CD38, CD56, kappa/lambda) on live cells | Reads the exact "DNA barcode" (VDJ gene sequence) unique to your myeloma clone |
| Needs a Saved Baseline Sample? | ✅ No—can be run on any patient at any time, even if no baseline sample was saved at diagnosis | ⚠️ Yes—requires a baseline bone marrow sample saved at diagnosis (identifies a trackable barcode in ~90% of patients) |
| Sensitivity & Cell Requirement | Reaches 10⁻⁵ (and up to 2 × 10⁻⁶) when at least 5 million fresh bone marrow cells are analyzed | Reaches 10⁻⁶ (1 in 1,000,000 cells) using DNA extracted from 2 million cells (works on fresh or frozen DNA) |
What This Means for You: When you read your MRD report, look at both the result (Negative vs. Positive) and the sensitivity number (10⁻⁵ vs. 10⁻⁶). Being MRD-negative at 10⁻⁶ (less than 1 cancer cell per million) gives an even stronger cushion against relapse than 10⁻⁵ (less than 1 per 100,000).
The "First-Pull" Rule: How to Prevent a False-Negative MRD Result
An MRD test is only as good as the bone marrow sample put into the tube. During your bone marrow biopsy, the very first 1 to 3 mL of liquid marrow drawn into the first syringe ("first pull") must be reserved for MRD testing. If the clinician sends the 3rd or 4th syringe pull instead, normal blood gets sucked into the syringe (hemodilution), watering down the marrow and potentially giving a "false-negative" MRD result.
Data Sources: NCCN Guidelines v2.2027 (Principles of MRD Testing, MYEL-E); IMWG 2016 MRD Consensus.
2. Best Timing to Test—and What Your Result Really Means
Because MRD testing requires a bone marrow biopsy, doctors do not run it every month—they save it for key decision points once your blood and urine markers are in Complete Response (CR) or near-zero Very Good Partial Response (VGPR):
| Key Testing Timepoint | Why Doctors Check MRD Here | What the Result Means for Your Care |
|---|---|---|
| 1. At Initial Diagnosis (Baseline) | Records your myeloma's unique DNA barcode (clonotype) | Essential preparation step so you can use NGS (clonoSEQ) MRD testing later on |
| 2. End of Induction / Day 100 After Transplant (or CAR-T) | Measures how deeply your initial therapy or stem cell transplant cleared the marrow | Establishes your first MRD benchmark (paired with a whole-body FDG-PET/CT scan) |
| 3. Every 12 Months During Maintenance | Checks whether MRD negativity holds steady for ≥ 1 year (Sustained MRD Negativity) | Sustained MRD negativity for 1 to 2+ years is the gold standard for long-term remission and guides maintenance discussions |
| 4. If MRD Turns Positive After Being Negative | Catches "MRD resurgence" (molecular relapse) months before blood M-protein rises | Signals that the clone is waking up; doctors tighten blood lab checks to every 4–8 weeks and prepare next-line options |
What This Means for You: What if you feel great and your blood M-protein is zero, but your bone marrow MRD test comes back Positive? Take a deep breath:
- A positive MRD test in remission is NOT a clinical relapse: In roughly 30% to 40% of patients in CR, a small number of residual plasma cells remain detectable. In many standard-risk patients (especially those with t(11;14) or an "MGUS-like" biological profile), those leftover cells sit quietly in a dormant state for many years as long as you stay on maintenance therapy.
- High-risk patients gain the biggest boost from MRD negativity: If you were diagnosed with high-risk genetics (like del(17p) or t(4;14) paired with 1q+), reaching and sustaining MRD negativity with a 4-drug regimen and transplant largely overcomes that high-risk label, lifting your outlook close to standard-risk patients.
Data Sources: NCCN Guidelines v2.2027 (MYEL-E, MYEL-F); IMWG 2016 Criteria; EHA-EMN 2025 Guidelines.
3. NCCN 2027 Guide: Can You Step Down or Stop Maintenance After Sustained MRD Negativity?
Once patients see "MRD-Negative (0 cells out of 1,000,000)" for a year or two in a row, the #1 question in the exam room is: "Can I finally stop taking my maintenance medication?"
In Version 2.2027 (MYEL-E), the NCCN Guidelines state that MRD negativity and Sustained MRD Negativity can help guide shared decision-making between you and your oncologist regarding stepping down (de-escalating) or adjusting maintenance therapy. However, whether it is safe to step down depends heavily on whether you are reducing from 2 drugs to 1 drug vs. stopping all drugs, and whether your myeloma is standard-risk or high-risk:
| Your Clinical Scenario | NCCN v2.2027 & Clinical Trial Guidance | Why Doctors Recommend This Path |
|---|---|---|
| 1. Stepping Down 2-Drug Maintenance to 1 Drug (De-Escalation) | ✅ Supported after 24 months: If you take daratumumab + lenalidomide (DR) maintenance for 2 years and hold Sustained MRD Negativity (10⁻⁵) for ≥ 12 months, you can discuss stopping daratumumab and continuing lenalidomide pills alone | Backed by the landmark Phase 3 PERSEUS trial and mSMART guidelines, where stepping down to lenalidomide alone after sustained MRD negativity delivered a 95.3% to 97.8% 4-year progression-free survival rate |
| 2. Stopping All Maintenance Completely in Standard-Risk Myeloma | ⚠️ Caution / Clinical Trial Preferred: Complete treatment-free observation after 2 consecutive MRD-negative tests (10⁻⁵ / 10⁻⁶ for ≥ 1–2 years) is promising in standard-risk patients, but continuous lenalidomide remains the routine standard outside trials | In the MASTER trial, standard-risk patients (0 high-risk features) had low relapse rates after stopping therapy under strict MRD monitoring; if side effects or personal preference lead you to stop, repeat MRD and blood checks closely |
| 3. High-Risk Myeloma (2025 IMS/IMWG High-Risk or ≥ 2 Hits) | 🛑 Do NOT stop all maintenance: Even after achieving Sustained MRD Negativity, high-risk patients (del(17p)/TP53, t(4;14) + 1q+, or R2-ISS 3.0–5.0 pts) should stay on continuous maintenance therapy | In the MASTER trial, ultra-high-risk patients who stopped all therapy after reaching MRD negativity had a high rate of rapid MRD return and relapse; continuous maintenance keeps aggressive clones locked down |
What This Means for You: Never stop your maintenance pills on your own after a single good bone marrow report. Think of stepping down from 2 drugs to 1 drug as a well-proven option once you have 12 to 24 months of Sustained MRD Negativity, whereas stopping completely (from 1 drug to 0 drugs) should only be done inside an MRD-guided clinical trial or through a carefully monitored shared decision with your myeloma specialist if you have standard-risk disease and significant drug side effects.
Data Sources: NCCN Guidelines v2.2027 (MYEL-E, MYEL-H); PERSEUS Trial (N Engl J Med 2024); MASTER Trial (J Clin Oncol 2022); MIDAS Trial (2025).
Common Pitfalls to Avoid
Pitfall 1: Stopping Maintenance Pills on Your Own After a Single MRD-Negative Report
❌ The Pitfall: Seeing "MRD-Negative" on your Day 100 post-transplant biopsy and deciding to quit your maintenance medication right away because you feel "cured."
✅ The Right Move: Remember that a single MRD-negative test is a snapshot, not the finish line. Long-term safety comes from Sustained MRD Negativity (≥ 12 to 24 months apart), and any reduction in maintenance should always be planned with your hematologist.
Pitfall 2: Panicking Because Your MRD Test Is Positive While You Are in Stable Remission
❌ The Pitfall: Feeling devastated or asking to switch to aggressive chemotherapy immediately because your bone marrow MRD test found 5 cells out of 1,000,000 while your blood M-spike is 0.0.
✅ The Right Move: Stay calm and look at the trend. If you are in a stable Complete Response or VGPR with no symptoms, continuing your current maintenance therapy often keeps small residual clones asleep for years.
Pitfall 3: Running an MRD Test Before Your Blood and Urine Markers Near Zero
❌ The Pitfall: Undergoing an invasive bone marrow biopsy specifically to check MRD when your blood SPEP still shows a 0.8 g/dL (8 g/L) M-spike.
✅ The Right Move: Wait until your blood and urine tests reach Complete Response (CR)—or at least a deep VGPR where only slow-clearing IgG protein remains—before scheduling a bone marrow MRD test.
Pitfall 4: Forgetting to Check Whole-Body PET-CT Alongside Bone Marrow MRD
❌ The Pitfall: Relying solely on a hip bone marrow MRD test when you originally had plasmacytomas or patchy bone disease elsewhere in your body.
✅ The Right Move: Pair your bone marrow MRD test with a whole-body FDG-PET/CT scan so your doctor can confirm Imaging plus MRD negativity from head to toe.
Summary: Your Quick Decision Guide
MRD Testing & Maintenance Step-Down Decision Pathway
Select your clinical situation or toggle inside any card to view NCCN v2.2027 & PERSEUS rules:
Testing Readiness & Method
Test only after SPEP/UPEP & FLC reach CR or deep VGPR
1st syringe pull goes to MRD tube to prevent dilution
Rules out focal myeloma spots outside the hip bone
MRD-Negative & Step-Down
2 negative tests ≥1 yr apart + negative PET/CT scan
After 24m Dara-Len + ≥12m MRD-, stop Dara & keep Len
Continue oral Len outside clinical trials or shared review
MRD-Positive Interpretation
30%–40% in CR keep a quiet, dormant MGUS-like clone
Do not switch to heavy chemo while blood M-spike is 0
Monitor SPEP & sFLC trends peacefully on therapy
Key Takeaways & Next Steps
- Make sure your baseline DNA is saved at diagnosis: Asking your doctor to bank your baseline bone marrow sample at diagnosis unlocks 10⁻⁶ NGS (clonoSEQ) tracking later in your journey.
- Aim for Sustained MRD Negativity (≥ 12 months): One negative test is great; two negative tests a year apart (paired with a clear PET/CT) is the true milestone that transforms long-term prognosis.
- Tailor maintenance to your genetic risk: Use Sustained MRD Negativity to discuss stepping down from 2-drug to 1-drug maintenance after 2 years, while respecting the need for ongoing maintenance protection if you have high-risk genetics.
Next Steps & Related Decision Guides
- Bone Marrow Biopsy & First-Pull Rule: Wondering why the first-pull 1–3 mL rule prevents false negatives? Read our Bone Marrow Biopsy Guide.
- Frontline Regimen Comparison: Understanding which 4-drug induction combinations drive the highest rates of MRD negativity? Explore our Frontline Treatment Playbook.
- Stem Cell Transplant Strategy: Deciding between upfront ASCT and cell banking? Review our Autologous Transplant Guide.
- Maintenance Therapy Deep-Dive: Navigating the PERSEUS protocol, lenalidomide vs. 2-drug maintenance, and side-effect management? Check our Maintenance Therapy Guide.
- High-Risk Genetics Playbook: Managing del(17p), TP53, and 1q21 amplification where continuous maintenance is mandatory? See our High-Risk Myeloma Guide.
- Imaging Scans in Myeloma: Why whole-body PET/CT or MRI is required alongside bone marrow MRD to rule out extramedullary disease? Review our Imaging Scans Guide.
5 Questions to Ask Your Doctor
- Did we save a baseline bone marrow sample for NGS MRD tracking?: "Do we have my diagnostic bone marrow DNA archived for clonoSEQ (NGS at 10⁻⁶), or will we use Next-Generation Flow (NGF at 10⁻⁵) when I reach remission?"
- Will you use the 'first pull' of bone marrow for my MRD tube?: "During my biopsy, can we make sure the very first 1 to 3 mL of liquid marrow goes into the MRD tube so blood dilution does not skew the result?"
- Should we pair my bone marrow MRD check with a PET-CT scan?: "To confirm full-body 'Imaging plus MRD negativity,' should we schedule a whole-body FDG-PET/CT around the same time?"
- If I achieve Sustained MRD Negativity for 12+ months, can we step down my maintenance?: "Once I complete 24 months of 2-drug maintenance (daratumumab + lenalidomide) with Sustained MRD Negativity, am I a candidate to stop daratumumab and continue lenalidomide alone?"
- Given my genetic risk profile, is it safe to ever pause maintenance completely?: "Based on the NCCN 2027 guidelines and my baseline FISH genetics, is it safer for me to stay on continuous maintenance or consider an MRD-guided trial?"
References
- National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Multiple Myeloma, Version 2.2027 (2026). Available at: https://www.nccn.org
- Kumar S, Paiva B, Anderson KC, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17(8):e328-e346.
- Sonneveld P, Dimopoulos MA, Boccadoro M, et al. Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma (PERSEUS). N Engl J Med. 2024;390(4):301-313.
- Costa LJ, Chhabra S, Medvedova E, et al. Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma (MASTER). J Clin Oncol. 2022;40(25):2901-2912.
- Dimopoulos MA, Terpos E, Boccadoro M, et al. EHA-EMN Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with multiple myeloma. HemaSphere / Nat Rev Clin Oncol. 2025.
This clinical decision guide is synthesized from international consensus guidelines and peer-reviewed literature for educational purposes only. It does not substitute for professional medical care. Consult your treating hematology-oncology team regarding diagnostic and treatment decisions.
CMDN Care · Myeloma Companion
Organize your lab reports, follow biomarker trends, and prepare questions for your care team with CMDN’s English-language companion for myeloma patients and caregivers.
Open CMDN CareHow CMDN Care worksSign in with Google or a secure email code.
Lab report OCR
Review results extracted from your reports.
Biomarker trends
Keep follow-up results in one place.
Visit preparation
Bring your questions to your care team.
FAQs
- If my blood and urine tests say I am in a Complete Response (CR), why do I still need an MRD test?
- A traditional Complete Response (CR) means your blood and urine M-protein are down to zero and fewer than 5% of your bone marrow cells look like plasma cells under a regular microscope. However, thousands of hidden myeloma cells can still lurk below the surface. An MRD test acts like a super-magnifying glass that checks 100,000 to 1,000,000 bone marrow cells to see if the cancer is truly gone at a microscopic level.
- What do 10⁻⁵ and 10⁻⁶ mean on my MRD report?
- They measure how deep the lab searched. MRD negativity at 10⁻⁵ (the minimum international standard) means zero myeloma cells were found among 100,000 healthy bone marrow cells. MRD negativity at 10⁻⁶ is ten times deeper—meaning zero myeloma cells were found among 1,000,000 healthy cells, which predicts an even longer remission.
- What is the difference between Flow (NGF) and Sequencing (NGS / clonoSEQ) MRD tests?
- Both are guideline-approved bone marrow MRD tests, but they work differently. Next-Generation Flow (NGF) uses laser color tags to spot abnormal surface proteins on fresh cells within hours and does not need a saved sample from when you were first diagnosed. Next-Generation Sequencing (NGS, such as clonoSEQ) reads the tumor's DNA barcode down to 10⁻⁶ and works on stored DNA, but it requires a baseline bone marrow sample saved at diagnosis.
- My MRD test came back positive even though I am in remission. Does that mean my treatment failed?
- No! Many patients who remain MRD-positive at 10⁻⁵ stay in a calm, stable remission for years on maintenance therapy. In these patients, the few remaining cells often behave like dormant, harmless MGUS cells held in check by your immune system and maintenance medication.
- If I achieve Sustained MRD Negativity, can I reduce or stop my maintenance medication?
- Under NCCN v2.2027 guidelines, Sustained MRD Negativity (two negative tests at least 12 months apart) can guide shared decision-making with your doctor to step down maintenance—for example, stopping daratumumab after 2 years of 2-drug maintenance while staying on lenalidomide pills (as proven in the PERSEUS trial). However, stopping all maintenance drugs completely outside a clinical trial is generally discouraged, especially if you have high-risk myeloma.
- Why does my doctor want a PET-CT scan at the same time as my bone marrow MRD test?
- A bone marrow biopsy only checks one spot in your hip bone. Because myeloma can occasionally hide in another bone or soft-tissue spot without showing up in the hip, pairing a negative bone marrow MRD test with a clear whole-body FDG-PET/CT confirms 'Imaging plus MRD negativity' across your entire body.
Related reading
References used for this guide
- NCCN Clinical Practice Guidelines in Oncology: Multiple Myeloma (Version 2.2027)
- IMWG Consensus Criteria for Response and Minimal Residual Disease Assessment in Multiple Myeloma (Lancet Oncol)
- PERSEUS Phase 3 Trial: Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Myeloma (N Engl J Med)
- MASTER Trial: MRD Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma (J Clin Oncol)
for their academic support:
for myeloma patients globally